Misha, an implantable shock absorber, treats people with medial knee OA. These patients failed to find relief from non-surgical or surgical treatment. This population continues to experience pain that interferes with daily activities.
Due to age or absence of advanced OA, they can’t or won’t undergo joint replacement. Misha can alleviate pain, improve function and potentially delay the need for total knee replacement in some patients.
The company says Misha represents the world’s first implantable shock absorber (ISA) for the knee.
Dr. Anil Ranawat, chief of the hip and knee division of the Sports Medicine Institute, Hospital for Special Surgery in New York, said in a news release that Misha “fills that void” between arthroscopic knee preservation and arthroplasty for surgeons and patients.
Anton Clifford, Moximed founder and CEO, called the regulatory nod “a milestone event for knee OA sufferers.”
“We’re thrilled to now be in a position to make the surgery available to patients,” Clifford said. “We are committed to providing excellent medical education and customer service, supporting selection and treatment of indicated patients, and demonstrating scalability of our business as we introduce the Misha knee system to the U.S.”
Fremont, California-based Moximed raised $40 million in a Series C equity and debt financing last August.
